Alkermes Plc (ALKS)

34.49
NASDAQ : Health Technology
Prev Close 34.09
Day Low/High 33.46 / 34.98
52 Wk Low/High 32.61 / 71.22
Avg Volume 756.50K
Exchange NASDAQ
Shares Outstanding 155.38M
Market Cap 5.30B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alkermes' Corporate Presentation To Be Webcast At Upcoming Healthcare Conferences

Alkermes' Corporate Presentation To Be Webcast At Upcoming Healthcare Conferences

DUBLIN, Nov. 6, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, Nov.

Alkermes Presents New Data On ALKS 4230 At Society For Immunotherapy Of Cancer's (SITC) 33rd Annual Meeting

Alkermes Presents New Data On ALKS 4230 At Society For Immunotherapy Of Cancer's (SITC) 33rd Annual Meeting

-- Initial Clinical Data From Ongoing Monotherapy Dose-Escalation Stage of Phase 1 Study to be Presented --

Alkermes Reports On Outcome Of FDA Advisory Committee Meeting On ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

Alkermes Reports On Outcome Of FDA Advisory Committee Meeting On ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

DUBLIN, Nov. 1, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced that the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.

Trading In Alkermes Ordinary Shares Halted Today

Trading In Alkermes Ordinary Shares Halted Today

-- FDA Advisory Committee to Review New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder --

Alkermes Announces Publication Of Phase 3 Data For ALKS 5461 For Adjunctive Treatment Of Major Depressive Disorder In Molecular Psychiatry

Alkermes Announces Publication Of Phase 3 Data For ALKS 5461 For Adjunctive Treatment Of Major Depressive Disorder In Molecular Psychiatry

-- ALKS 5461 Demonstrated Consistent Profile of Antidepressant Activity, Safety and Tolerability in Two Phase 3 Studies --

Alkermes Announces Recipients Of 3rd Annual ALKERMES INSPIRATION GRANTS®

Alkermes Announces Recipients Of 3rd Annual ALKERMES INSPIRATION GRANTS®

- Competitive Grant Program Awards $1 Million to 14 Organizations for the Development or Expansion of Programs Designed to Serve Those Affected by Mental Health or Substance Use Disorders -

Alkermes Plc Reports Third Quarter 2018 Financial Results

Alkermes Plc Reports Third Quarter 2018 Financial Results

-- Third Quarter Revenues Increased to $248.7 Million, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales --

Alkermes Highlights Ongoing Commitment To Research And Innovation In Depression And Schizophrenia At 2018 Psych Congress

Alkermes Highlights Ongoing Commitment To Research And Innovation In Depression And Schizophrenia At 2018 Psych Congress

DUBLIN, Oct. 17, 2018 /PRNewswire/ --   Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando, Oct.

Alkermes To Host Conference Call To Discuss Third Quarter 2018 Financial Results

Alkermes To Host Conference Call To Discuss Third Quarter 2018 Financial Results

DUBLIN, Oct. 16, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.

Alkermes Initiates Clinical Evaluation Of Novel Immuno-Oncology Drug Candidate ALKS 4230 In Combination With PD-1 Inhibitor Pembrolizumab

Alkermes Initiates Clinical Evaluation Of Novel Immuno-Oncology Drug Candidate ALKS 4230 In Combination With PD-1 Inhibitor Pembrolizumab

-- Ongoing Phase 1 Study Expanded to Assess Safety and Anti-Tumor Activity of ALKS 4230 With Pembrolizumab in Patients With Advanced Solid Tumors --

Alkermes Announces 3rd Annual Competitive Grants Program To Support Those Affected By Mental Health And Substance Use Disorders

Alkermes Announces 3rd Annual Competitive Grants Program To Support Those Affected By Mental Health And Substance Use Disorders

-- ALKERMES Inspiration Grants® Program Will Award Up to $1 Million for the Development or Expansion of Innovative Programs --

Alkermes' Corporate Presentation To Be Webcast At The 38th Annual Canaccord Genuity Growth Conference

Alkermes' Corporate Presentation To Be Webcast At The 38th Annual Canaccord Genuity Growth Conference

DUBLIN, Aug. 1, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, Aug.

Alkermes Plc Reports Second Quarter 2018 Financial Results

Alkermes Plc Reports Second Quarter 2018 Financial Results

-- Second Quarter Revenues Increase to $304.6 Million, Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales --

Alkermes To Host Conference Call To Discuss Second Quarter 2018 Financial Results

Alkermes To Host Conference Call To Discuss Second Quarter 2018 Financial Results

DUBLIN, July 19, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.

FDA Approves ARISTADA INITIO™ For The Initiation Of ARISTADA® For Schizophrenia

FDA Approves ARISTADA INITIO™ For The Initiation Of ARISTADA® For Schizophrenia

-- Novel Regimen Enables Physicians to Fully Dose Up to Two Months of ARISTADA Treatment on Day One --

Alkermes To Present At Goldman Sachs 39th Annual Global Healthcare Conference

Alkermes To Present At Goldman Sachs 39th Annual Global Healthcare Conference

DUBLIN, June 6, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13,...

Alkermes Receives $50 Million Payment From Biogen Following Review Of Preliminary Gastrointestinal Tolerability Data From The Ongoing BIIB098 Clinical Development Program

Alkermes Receives $50 Million Payment From Biogen Following Review Of Preliminary Gastrointestinal Tolerability Data From The Ongoing BIIB098 Clinical Development Program

-- Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile --

American Airlines Is Caught in a Downward Current, Plus 4 Other Stocks That Look Good Short

AAL, UBS, CYOU, LOGM and ALKS were all recently downgraded by TheStreet's Quant Ratings service.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ENVA, ERIC, GM, MHH, PJC, SONA, SVVC Downgrades: ALKS, APOG, IDT, MJCO, TYPE Initiations: CKPT Read on to get TheStreet Quant Ratings' detailed report:

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

Two to Buy on the Dip

Two to Buy on the Dip

Talk of intensifying trade war is creating some bargains for investors.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Alkermes Plc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Alkermes Plc

Levi & Korsinsky announces it has commenced an investigation of Alkermes plc ("Alkermes" or "the Company") (NASDAQGS:ALKS) concerning possible violations of federal securities laws.

Dow Comes Off Session Lows, Finishes Day Down More Than 400 Points

Dow Comes Off Session Lows, Finishes Day Down More Than 400 Points

Stocks finish down sharply on Monday, the first trading day of the second quarter, after China's Ministry of Finance announces new tariffs of up to 25% on certain U.S. products.

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.

TheStreet Quant Rating: D (Sell)